These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 29895526)
1. Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ Endocr Relat Cancer; 2018 Oct; 25(10):853-864. PubMed ID: 29895526 [TBL] [Abstract][Full Text] [Related]
2. Activity of roniciclib in medullary thyroid cancer. Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ Oncotarget; 2018 Jun; 9(46):28030-28041. PubMed ID: 29963260 [TBL] [Abstract][Full Text] [Related]
3. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135 [TBL] [Abstract][Full Text] [Related]
4. Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ Oncotarget; 2017 Sep; 8(40):67990-68000. PubMed ID: 28978090 [TBL] [Abstract][Full Text] [Related]
5. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531 [TBL] [Abstract][Full Text] [Related]
7. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer. Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728 [TBL] [Abstract][Full Text] [Related]
8. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932 [TBL] [Abstract][Full Text] [Related]
9. Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells. Hua SC; Chang TC; Chen HR; Lu CH; Liu YW; Chen SH; Yu HI; Chang YP; Lee YR Pharm Res; 2012 Jul; 29(7):1990-2005. PubMed ID: 22477067 [TBL] [Abstract][Full Text] [Related]
10. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. Ruan M; Liu M; Dong Q; Chen L J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040 [TBL] [Abstract][Full Text] [Related]
12. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer. Lee HJ; Lee WK; Kang CW; Ku CR; Cho YH; Lee EJ Cancer Lett; 2018 Mar; 417():131-140. PubMed ID: 29306020 [TBL] [Abstract][Full Text] [Related]
13. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886 [TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer. Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506 [TBL] [Abstract][Full Text] [Related]
15. Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells. Sawa A; Chiba T; Ishii J; Yamamoto H; Hara H; Kamma H Endocr J; 2017 Nov; 64(11):1115-1123. PubMed ID: 28855436 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer. Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266 [TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Chen G; Nicula D; Renko K; Derwahl M Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253 [TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Bahleda R; Grilley-Olson JE; Govindan R; Barlesi F; Greillier L; Perol M; Ray-Coquard I; Strumberg D; Schultheis B; Dy GK; Zalcman G; Weiss GJ; Walter AO; Kornacker M; Rajagopalan P; Henderson D; Nogai H; Ocker M; Soria JC Br J Cancer; 2017 Jun; 116(12):1505-1512. PubMed ID: 28463960 [TBL] [Abstract][Full Text] [Related]
19. Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation. Ayroldi E; Petrillo MG; Marchetti MC; Cannarile L; Ronchetti S; Ricci E; Cari L; Avenia N; Moretti S; Puxeddu E; Riccardi C Cell Death Dis; 2018 Feb; 9(3):305. PubMed ID: 29467389 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]